-+ 0.00%
-+ 0.00%
-+ 0.00%

Cytokinetics to file FDA sNDA for aficamten in non-obstructive HCM in Q4 2026

PUBT·08/28/2026 09:45:38
Listen to the news
Cytokinetics to file FDA sNDA for aficamten in non-obstructive HCM in Q4 2026
  • Cytokinetics plans to file a supplemental New Drug Application with the FDA in Q4 2026 for aficamten in symptomatic non-obstructive HCM.
  • Move follows positive Phase 3 ACACIA-HCM results, meeting dual primary endpoints at 36 weeks on KCCQ-CSS and pVO2.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608280545PRIMZONEFULLFEED9817581) on August 28, 2026, and is solely responsible for the information contained therein.